2027 Hair Regrowth Race Heats Up

Money is pouring into a decades-stalled corner of medicine: curing baldness, not just covering it up.

Quick Take

Pelage Pharmaceuticals closed a $120 million Series B round to advance PP405, a topical drug meant to wake up dormant hair follicles.
Veradermics raised $75 million, then $150 million more, to push an extended-release oral minoxidil pill through late-stage trials.
Two startups alone pulled in a combined $270 million last October for treatments targeting androgenetic alopecia, the most common form of hair loss.
Analysts say some new treatments could reach pharmacy shelves as early as 2027, a timeline that has investors moving fast.

A Cash Wave Hits A Neglected Market

Pelage Pharmaceuticals announced on October 15 that it closed a $120 million Series B round. ARCH Venture Partners and GV, formerly Google Ventures, co-led the deal. The money will push PP405, a topical treatment designed to reactivate dormant hair follicle stem cells, toward Phase 3 trials in 2026. It marks the company’s third major raise since 2023, following a $14 million Series A and a $16.75 million seed round.

Pelage isn’t alone. Veradermics closed a $75 million Series B in late 2024 to fund a Phase 2/3 trial, then followed up with an oversubscribed $150 million Series C led by SR One. That later round targets an extended-release oral minoxidil pill for pattern hair loss, a condition the company says affects roughly 80 million Americans. Together, the two firms’ fundraising totals rank among the largest bets ever placed on baldness treatment.

Why Investors Suddenly Care About Bald Spots

Bloomberg reporter Avalon Pernell noted that some of these treatments could seek regulatory approval and reach the market as soon as 2027. That timeline draws investor interest because consumers already spend heavily on hair loss remedies, even ones that barely work. The Food and Drug Administration hasn’t approved a new baldness drug in nearly three decades, so a real breakthrough would enter a market starved of options.

Pelage’s Phase 2a trial results gave backers something concrete to point to. The company reported the trial met its primary safety endpoint, with no systemic absorption detected in a randomized, controlled study of men and women with androgenetic alopecia. Men with more severe hair loss showed a rapid, visible response even after just four weeks of dosing. Results like these turn a cosmetic annoyance into something that looks more like solvable biology.

The Broader Market Bet Behind The Headlines

Market research firms have circled androgenetic alopecia for years, with estimates ranging from under $1 billion to nearly $5 billion depending on which analyst you ask and which year they’re counting. Grand View Research pegs the global market at $2.7 billion in 2023, growing toward $4.76 billion by 2030. Those numbers rest on assumptions about pricing and repeat use, not proven sales, but they give venture capital firms a growth story to underwrite bigger checks.

That framing matters. Investors and founders both benefit when hair loss gets described as a large, underserved medical condition rather than a cosmetic nuisance most people quietly accept. The medical framing supports higher valuations and makes it easier to recruit co-investors for follow-on rounds. It also raises the stakes if a flagship drug candidate stumbles in later-stage trials, since so much capital now rides on a handful of companies.

Other Players Are Circling The Same Opportunity

Pelage and Veradermics aren’t the only names drawing checks. Amplifica Holdings Group, a University of California Irvine spinout, closed an oversubscribed $26 million Series B with backing from Eli Lilly and Company for its own pipeline of injectable alopecia treatments. Absci also drew a $40 million strategic investment from Eli Lilly as part of a larger $100 million offering, signaling that big pharmaceutical names want exposure to this space too.

The pattern is clear even without a single dominant winner yet. Multiple biotech firms, backed by venture capital heavyweights and at least one major drugmaker, are racing toward the same finish line: a treatment that regrows hair rather than just slowing its loss. Whether any of them clears the Food and Drug Administration’s bar by 2027 remains to be seen, but the money is already committed.

For an industry that hasn’t seen a genuinely new approved baldness drug since the 1990s, that alone counts as news. Consumers spend billions annually chasing thinner promises, from supplements to laser combs, and a scientifically backed option would reshape that entire market overnight.